ESA Use in Multiple Myeloma Dialysis Patients

Introduction to ESA Therapy

The European Myeloma Network emphasizes that with modern effective combination therapies that rapidly control myeloma, the systematic need for ESAs is debatable, particularly in patients with hemoglobin levels below 10 g/dL 1, 2

Start ESAs only when hemoglobin falls below 10 g/dL with documented symptomatic anemia, not prophylactically, and after excluding reversible causes such as iron deficiency, vitamin B12 deficiency, and hemolysis 1, 2
Before initiating any ESA, exclude and correct iron deficiency by checking ferritin and transferrin saturation, vitamin B12 deficiency, hemolysis, and functional iron deficiency, which is common and causes ESA hyporesponsiveness 1, 2, 4

For dialysis patients with multiple myeloma, use epoetin alfa 40,000 U subcutaneously weekly, epoetin beta 30,000 U subcutaneously weekly, or darbepoetin 150 μg weekly or 500 μg every 3 weeks 1, 2, 3

The thromboembolic risk is markedly elevated in multiple myeloma patients, especially those receiving thalidomide or lenalidomide with dexamethasone or doxorubicin, with ESAs increasing the relative risk of thromboembolic events by 67% compared to placebo (RR 1.67; 95% CI: 1.35-2.06) 5
Implement thromboprophylaxis concurrently, with aspirin 100 mg daily for 0-1 individual risk factors, and low-molecular-weight heparin (LMWH) or full-dose warfarin for ≥2 risk factors or high-dose dexamethasone/multiagent chemotherapy 1, 2

Target hemoglobin range is 10-12 g/dL; never exceed 12 g/dL, as exceeding this level increases cardiovascular and thromboembolic risks as well as possibly mortality 1, 2, 5
Discontinue ESAs after 6-8 weeks if adequate hemoglobin response is not achieved (defined as <1 g/dL increase at 4-6 weeks) 1, 2, 3

Most patients require concurrent intravenous iron to optimize ESA response and minimize required ESA doses, with standard dosing being IV iron sucrose 1000 mg total dose 1, 2, 4
For dialysis patients, administer IV iron if ferritin <200 ng/mL and transferrin saturation <20% 4
Functional iron deficiency during ESA treatment should be treated with IV iron (grade 1A recommendation) 1, 2